Feature|Videos|April 14, 2026 (Updated: April 23, 2026)

Beyond the Excipient: Drug Formulation from Discovery Through Commercialization

Author(s)Paul Smaltz, BASF

Key Takeaways

  • Learn how to overcome complex formulation challenges, such as bioavailability and solubility, by leveraging the technical expertise of your excipient suppliers.
  • Understand how BASF’s Virtual Pharma Assistants help customers formulate faster.
SHOW MORE

Paul Smaltz, Senior Vice President of BASF Pharma Solutions, explains how the company acts as a strategic partner to the pharmaceutical industry by integrating AI-driven formulation tools, sustainability initiatives, and specialized biopharmaceutical solutions to overcome modern manufacturing challenges.

As the pharmaceutical landscape shifts toward asset-light models and increased outsourcing, BASF is evolving beyond its role as a traditional excipient manufacturer to provide deep technical expertise and R&D support. Through the implementation of generative AI and the ZoomLab® predictive modeling tool, BASF is helping customers accelerate formulation timelines and solve complex bioavailability issues with unprecedented precision. Smaltz also discusses the BASF commitment to "green transformation," pointing to the company’s goal of reaching net-zero emissions by 2050 while delivering high-performance and sustainable solutions for the growing biopharmaceutical market.


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.